Patent search ap:("Array BioPharma Inc." OR "Genentech Page Inc.") AND inv:"Tony P. Tang"

21.

发明授权
KRas G12C inhibitors 有权

公开(公告)号：US10647715B2

公开(公告)日：2020-05-12

申请号：US16412091

申请日：2019-05-14

Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.

Inventor： Matthew Arnold Marx , Thomas P. Bobinski , Aaron Craig Burns , John Gaudino , Julia Haas , John Michael Ketcham , John David Lawson , Brad Newhouse , Spencer Pajk , Christopher Ronald Smith , Tony P. Tang

IPC: C07D471/04 , A61P35/00 , C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

22.

发明授权
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases 有权

公开(公告)号：US10208024B2

公开(公告)日：2019-02-19

申请号：US15333148

申请日：2016-10-24

Applicant: Array BioPharma, Inc.

Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang

IPC: C07D403/14 , C07D401/14 , C07D413/14 , A61K31/501 , A61K31/5377 , C12Q1/68 , A61K45/06 , C12Q1/6886 , G01N33/574

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

23.

发明申请
SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS 审中-公开

公开(公告)号：US20180133207A1

公开(公告)日：2018-05-17

申请号：US15860894

申请日：2018-01-03

Applicant: Array BioPharma, Inc.

Inventor： Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls

IPC: A61K31/4545 , A61K45/06 , A61P35/00 , A61P35/02 , A61K31/444 , A61K31/506 , A61K31/501 , A61K31/497 , A61K31/5377

CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04

Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

24.

发明申请
4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS 审中-公开

公开(公告)号：US20170362240A1

公开(公告)日：2017-12-21

申请号：US15532937

申请日：2015-12-04

Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION

Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett

IPC: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06

CPC classification number: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

25.

发明授权
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases 有权

公开(公告)号：US12180207B2

公开(公告)日：2024-12-31

申请号：US17416117

申请日：2019-12-13

Applicant: ARRAY BIOPHARMA INC.

Inventor： James F. Blake , David A. Moreno , Li Ren , Tony P. Tang , Shane M. Walls

IPC: C07D471/04 , A61P35/00 , C07D519/00

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which Ring A, Ring B, Ring C, R1, R2, L, Y, and W have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

26.

发明申请
2-ARYL- AND 2-HETEROARYL-SUBSTITUTED 2-PYRIDAZIN-3(2H)-ONE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES 审中-公开

公开(公告)号：US20190300511A1

公开(公告)日：2019-10-03

申请号：US16276326

申请日：2019-02-14

Applicant: Array BioPharma Inc.

Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang

IPC: C07D403/14 , C07D413/14 , C07D401/14 , G01N33/574 , A61K31/501 , A61K45/06 , A61K31/5377 , C12Q1/6886

Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

27.

发明申请
4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS 审中-公开

公开(公告)号：US20190177328A1

公开(公告)日：2019-06-13

申请号：US16212493

申请日：2018-12-06

Applicant: Array BioPharma Inc. , Celgene Corporation

Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett

IPC: C07D487/04 , A61K45/06 , A61K31/4985 , A61K31/5377

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

28.

发明授权
4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors 有权

公开(公告)号：US10189845B2

公开(公告)日：2019-01-29

申请号：US15532937

申请日：2015-12-04

Applicant: ARRAY BIOPHARMA INC. , CELGENE CORPORATION

Inventor： Shelley Allen , Mark Laurence Boys , Mark J. Chicarelli , Jay Bradford Fell , John P. Fischer , John Gaudino , Erik James Hicken , Ronald Jay Hinklin , Christopher F. Kraser , Ellen Laird , John E. Robinson , Tony P. Tang , Laurence E. Burgess , Robert Andrew Rieger , Jed Pheneger , Yoshitaka Satoh , Katerina Leftheris , Raj K. Raheja , Brydon L. Bennett

IPC: A61K45/06 , C07D487/04 , A61K31/4985 , A61K31/5377

Abstract: Compounds of Formula I: and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3 and R4 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of JAK kinase-associated diseases and disorders, such as autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.